(1R,2R)-反式-1,2-环戊烷二胺二盐酸盐 | 1030390-38-5

• 物质功能分类: 化学试剂 - 有机试剂 - 多胺
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1R,2R)-反式-1,2-环戊烷二胺二盐酸盐
• 英文名称: trans-Cyclopentane-1,2-diamine dihydrochloride
• 英文别名: (1R,2R)-cyclopentane-1,2-diamine;dihydrochloride
• CAS: 1030390-38-5
• 化学式: C5H14Cl2N2
• 分子量: 173.08
• InChiKey: VZCLGIZICFQJBX-ALUAXPQUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.67
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  4
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。
• PYRAZINECARBOXAMIDE COMPOUND
  申请人：ASTELLAS PHARMA INC.

  公开号：US20140323463A1

  公开（公告）日：2014-10-30

  [Problem] A compound which is useful as an inhibitor on EGFR T790M mutation kinase activity is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory action on an EGFR T790M mutation kinase, and have found that a pyrazinecarboxamide compound has an inhibitory action on an EGFR T790M mutation kinase, thereby completing the present invention. The pyrazinecarboxamide compound of the present invention has an inhibitory action on an EGFR T790M mutation kinase, and can be used as an agent for preventing and/or treating EGFR T790M mutation positive cancer, in another embodiment, EGFR T790M mutation positive lung cancer, in a still other embodiment, EGFR T790M mutation positive non-small cell lung cancer, in further still another embodiment, EGFR T790M mutation protein positive cancer, in further still another embodiment, EGFR T790M mutation protein positive lung cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant lung cancer, and in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer, or the like.

  提供一种作为EGFR T790M突变激酶活性抑制剂的化合物。 解决方案的手段 本发明人调查了一种对EGFR T790M突变激酶具有抑制作用的化合物，并发现吡嗪羧酰胺化合物对EGFR T790M突变激酶具有抑制作用，从而完成了本发明。本发明的吡嗪羧酰胺化合物对EGFR T790M突变激酶具有抑制作用，并可用作预防和/或治疗EGFR T790M突变阳性癌症的药剂，在另一实施例中，EGFR T790M突变阳性肺癌，在另一实施例中，EGFR T790M突变阳性非小细胞肺癌，在进一步的另一实施例中，EGFR T790M突变蛋白阳性癌症，在进一步的另一实施例中，EGFR T790M突变蛋白阳性肺癌，在进一步的另一实施例中，EGFR酪氨酸激酶抑制剂耐药癌症，在进一步的另一实施例中，EGFR酪氨酸激酶抑制剂耐药肺癌，在进一步的另一实施例中，EGFR酪氨酸激酶抑制剂耐药非小细胞肺癌等。
• [EN] SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER<br/>[FR] PYRIMIDINES SUBSTITUÉES POUR LE TRAITEMENT DU CANCER
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010106097A1

  公开（公告）日：2010-09-23

  The present invention encompasses compounds of general formula (1) wherein B, R1 to R5, Rx, m and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use in such treatment.

  本发明涵盖了一般式（1）中的化合物，其中B、R1至R5、Rx、m和n的定义如权利要求书中所述，这些化合物适用于治疗由细胞过度或异常增殖特征的疾病，并且适用于此类治疗。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。
• NEW COMPOUNDS
  申请人：SAPOUNTZIS Ioannis

  公开号：US20110071158A1

  公开（公告）日：2011-03-24

  The present invention encompasses compounds of general formula (1) wherein B, R 1 to R 5 , R x , m and n are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use in such treatment.

  本发明涵盖了一般式（1）的化合物，其中B、R1至R5、Rx、m和n如权利要求1所定义，适用于治疗由过度或异常细胞增殖所特征的疾病，并且它们在这种治疗中的使用。